WallStSmart

SRAX Inc (SRAX)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 1295% more annual revenue ($258.90M vs $18.55M). ZEPP leads profitability with a -15.5% profit margin vs -84.8%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

SRAX

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 4.0Value: 5.0Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for SRAX.

ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SRAX0 strengths · Avg: 0/10

No standout strengths identified

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

SRAX4 concerns · Avg: 2.3/10
Market CapQuality
$294,3803/10

Smaller company, higher risk/reward

Return on EquityProfitability
-337.0%2/10

ROE of -337.0% — below average capital efficiency

Revenue GrowthGrowth
-75.4%2/10

Revenue declined 75.4%

EPS GrowthGrowth
-46.2%2/10

Earnings declined 46.2%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : SRAX

SRAX has a balanced fundamental profile.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : SRAX

The primary concerns for SRAX are Market Cap, Return on Equity, Revenue Growth.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

SRAX profiles as a turnaround stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 29/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

SRAX Inc

TECHNOLOGY · SOFTWARE - APPLICATION · USA

SRAX, Inc., a technology company, focused on improving communications between public companies and their shareholders and investors in the United States. The company is headquartered in Westlake Village, California.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?